Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD PharmaTimesEarly safety and efficacy signals support move into repeatdose phase 2a trialOphthalmologyRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) PharmaTimes Early safety and efficacy signals support move into repeatdose phase 2a trial Ophthalmology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly, Gilead lead pharma’s M&A boomNext: BMS’ Sotyktu secures EC approval for psoriatic arthritis Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
